Steroids Powder Estradiol Benzoate
Quick Details
Product name | Estradiol benzoate |
Other name | 17-beta-oestradiol3-benzoate ; β-Estradiol 3-benzoate |
CAS register number | 50-50-0 |
EINECS | 200-043-7 |
Molecular formula | C25H28O3 |
Molecular weight | 376.49 |
Molecular structure |
|
Melting point | 192~198°C |
Assay | 98% |
Description
Estradiol Benzoate is a sex hormone that is present in both males and females, and is the most important form of estrogen in humans. In women, it plays a key role in the development and functioning of the reproductive system, as well as in the growth of certain bones. It also governs the distribution of body fat in women and is the main hormone responsible for the fact that women are shorter than men, on average. Both the ovaries and the adrenal glands produce it.
As a sex hormone, it also triggers many of the developments of the reproductive system that begin in puberty. It is present throughout the reproductive years, and declines during and after menopause. This decline is precisely what causes many of the symptoms of menopause, such as hot flashes and night sweats, vaginal dryness, and the loss of bone mass that may lead to osteoporosis.
Specification:
ITEM | SPECIFICATION |
| Assay | ≥99% |
| Description | White powder |
| Specific rotation | +55°~+59° |
| Loss on drying | ≤1% |
| Total heavy metals | ≤10ppm |
product Name | estradiol benzoate |
| Synonyms | beta-Estradiol-3-benzoate; Oestradiol Benzoate; 17beta-Estradiol benzoate |
| Molecular Formula | C25H28O3 |
| Molecular Weight | 376.488 |
| InChI | InChI=1/C25H28O3/c1-25-14-13-20-19-10-8-18(28-24(27)16-5-3-2-4-6-16)15-17(19)7-9-21(20)22(25)11-12-23(25)26/h2-6,8,10,15,20-23,26H,7,9,11-14H2,1H3/t20-,21-,22+,23+,25+/m1/s1 |
| CAS Registry Number | 50-50-0 |
| EINECS | 200-043-7 |
| Density | 1.185g/cm3 |
| Melting point | 191-198°C |
| Boiling point | 531.2°C at 760 mmHg |
| Refractive index | 1.604 |
| Flash point | 212°C |
| Vapour Pressur | 4.08E-12mmHg at 25°C |
Usage
Estradiol is the major estrogen secreted by the premenopausal ovary. Estradiol benzoate is an
estradiol analog which contains a benzyl ester at the C-3 position. Estradiol benzoate is useful in the
treatment of lesions produced by diminution of bodily production of estrogens.
Estradiol benzoate (INN; brand names Agofollin, Diffolisterol, Progynon-B, many others), or oestradiol benzoate (BAN), is a synthetic ester, specifically the 3-benzoyl ester, of the natural estrogen, estradiol. It was the first form of estrogen to be marketed, patented by Schering-Kahlbaum in 1936 in an oil preparation for injectable use and introduced later that year as Progynon-B. Though it is still in widespread use today, it has been mostly superseded by newer forms of estradiol with improved pharmacokinetics that require less frequent administration such as estradiol cypionate and estradiol valerate.
Application
Women's menstrual cycle involves several predictable changes in hormone levels, of which Estradiol Benzoateis one of them. Participate in the ovulation process, prepare the endometrial implant, the egg should be fertilized. Some tests on baboons and other primates show that his hormones also play a sustained role in maintaining pregnancy and contribute to the duration of pregnancy.
As a sex hormone, Estradiol Benzoatealso triggers many of the development of adolescent reproductive systems. It exists throughout the reproductive year and falls during and after menopause. This decline is the result of many symptoms of menopausal symptoms, such as hot flashes and night sweats, vaginal dryness and bone loss that may lead to osteoporosis.
COA
Product name | Estradiol Benzoate | |
Appearance | White crystalline powder | |
Water | ≤3.5% | pass |
Assay | 97 .0~ 103.0% | 99.2% |
Loss on drying | ≤0.5% | 0.17% |
Related substances | total impurities ≤1.0% | Pass |
any individual impurity ≤0.5% | Pass | |
Residual solvents | ethanol ≤0.5% | Pass |
Dosge
A single dose of 2.5 mg estradiol benzoate by intramuscular injection was found to produce plasma estradiol levels of >400 pg/mL, measured 24 hours post-injection, in a group of patients with minimal baseline levels of estradiol (due to GnRH analogue therapy with triptorelin).
